Headquartered in Warsaw, IN Fiscal year ends December NYSE: ZBH zimmerbiomet.com
Zimmer Biomet Holdings, Inc. is a global medical technology company with a comprehensive portfolio focused on musculoskeletal health. Its product categories include knee and hip replacement implants, sports medicine, extremities, trauma, craniomaxillofacial and thoracic devices (collectively S.E.T.), as well as technology and data solutions, bone cement, and surgical products. The company integrates digital and robotic technologies — notably the ROSA robotic surgical platform — with data analytics and artificial intelligence to enhance surgical precision and patient outcomes. With over 90 years of history, Zimmer Biomet operates in more than 25 countries and sells products in over 100 countries. In April 2025, the company acquired Paragon 28, Inc., expanding its foot-and-ankle portfolio within the extremities segment. Updated
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made…
Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with Iran are progressing positively, as we get ready to start another trading week, with the same issues that…
Pre-Market Stock Futures: Futures are trading mixed after a solid start to the week, with all the major indices, except the Russell 2000, finishing the day higher. Anticipation of earnings reports from…
Pre-Market Stock Futures: The futures are little changed after a blockbuster day to open the first full trading week of 2026. The combination of no Santa Claus rally, the market shrugging off…
Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last…
Live Updates Tuesday Wrap-up4:01pm ETThe Vanguard S&P 500 ETF closed at 571.95 Tuesday, down 0.4%. Netflix Upgraded12:09pm ETBMO Capital raised its price target on S&P 500 component company Netflix (Nasdaq: NFLX |…
Stifel recommends “defensive value” stocks for the remainder of 2025, and the firm has these five rated Buy.
Live Updates Close, But No Cigar4:06pm ETWell, the S&P 500 gave it the ol’ college try, but ultimately came up short. After nine straight days of up markets, a 20-year record, the…
Tuesday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Boston Scientific, Ciena, CrowdStrike, Emerson Electric, Kimco Realty, Nike, NovoCure and Zimmer Biomet.
Wednesday's top analyst upgrades and downgrades included Antero Resources, Array Technologies, Bumble, Chewy, EQT, LendingClub, Match, MGIC Investment, Nasdaq, New York Community Bancorp, Palo Alto Networks, Radian, Range Resources, Spotify Technology and Welltower.
Monday's top analyst upgrades and downgrades included BlackBerry, Cardinal Health, Comstock Resources, Howmet Aerospace, JD.com, Pacific Biosciences of California, Restaurant Brands, Tenaris and Wendy’s.
Monday's top analyst upgrades and downgrades included Arista Networks, Array Technologies, Ballard Power Systems, Caterpillar, Charles Schwab, Chewy, Coterra Energy, DocuSign, Gap, General Electric, KeyCorp, Marathon Petroleum, Marvell Technology, Roblox, Shoals Technologies,…
Tuesday's top analyst upgrades and downgrades included Campbell Soup, DoorDash, Eli Lilly, Enterprise Products Partners, Mastercard, Oracle, Silvergate Capital, Uber Technologies, VICI Properties, Visa and Welltower.
Friday's top analyst upgrades and downgrades included Ally Financial, American Express, AppLovin, AstraZeneca, Coinbase Global, Cognizant Technology Solutions, Comcast, CME, CrowdStrike, Delta Air Lines, Danaher, Dropbox, Marathon Oil, Microsoft and Target.
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Bilibili, Cognizant Technologies, Dynatrace, Equinix, Herbalife Nutrition, Match, Nutrien, Robinhood Markets, Roku and Zillow.
Zimmer Biomet Holdings, Inc. is a global medical technology company with a comprehensive portfolio focused on musculoskeletal health.
24/7 Wall St.'s 12-month price target for ZBH is $111.91, rated Buy. The Wall Street consensus target is $107.23. ZBH price prediction →
